Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 1.00 |
| ▸ | FXR2 | P51116 | 1/20 | 0.86 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087849 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL1163928 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL17087853 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL12168956 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL29880955 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL12879039 | 1.00 | NR1H4 (1.00) | NR1H4FXR2HSD17B13 | |
| SCHEMBL1164201 | 0.94 | NR1H4 (0.90) | NR1H4FXR2HSD17B13 | |
| SCHEMBL29880621 | 0.94 | NR1H4 (0.90) | NR1H4FXR2HSD17B13 | |
| SCHEMBL24585950 | 0.94 | NR1H4 (0.89) | NR1H4FXR2HSD17B13 | |
| SCHEMBL12808764 | 0.93 | NR1H4 (0.87) | NR1H4FXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077268-B2 | FXR agonists and methods for making and using | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-09-18 | — | — | US | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2017078928-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-12-29 | — | — | US | disclosed |
| WO-2015138986-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | NR1H4 10/4885FXR2 6/4885HSD17B13 1618/4885 |
| US-10077268-B2 | FXR agonists and methods for making and using | NR1H4, FXR2, FXR1 | NR1H4 1/4885FXR2 2/4885HSD17B13 573/4885 |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | NR1H4, FXR2, FXR1 | NR1H4 1/4885FXR2 2/4885HSD17B13 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.